Getinge Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Getinge Business Model Canvas: A strategic download for investors and leaders
Explore Getinge's business model in a clear, decision-ready format-our Business Model Canvas shows how the company delivers value across intensive care, cardiovascular procedures, operating rooms, sterile reprocessing, and life science workflows; a practical guide for understanding customer segments, monetization logic, and the operational strengths behind the brand.
Partnerships
Strategic Component Suppliers
Getinge depends on a global network of specialized suppliers for high-grade medical components and raw materials, with about 60% of critical parts sourced from 120 certified vendors across Europe and Asia as of 2024.
These partnerships secure quality and reliability for ventilators and heart-lung machines; joint quality-control agreements reduced supplier-related defects by 42% from 2020-2024.
Contracts include shared audits and CAPA processes to meet MDR (EU Medical Device Regulation) and FDA standards, lowering regulatory nonconformity incidents by 35% in 2023.
Research and Academic Institutions
Getinge partners with top universities and CROs to run clinical trials and co-develop surgical and ICU tech, funding or collaborating on over 120 trials since 2020 and citing a 15% share of R&D-linked revenue impact in 2024; these ties accelerate next-gen devices and keep Getinge aligned with evidence-based practice and peer-reviewed outcomes.
Digital Health and Software Providers
Partnerships with tech firms let Getinge embed AI and analytics into devices, improving ICU workflow and remote monitoring; in 2024 Getinge reported €2.9bn revenue and increased digital-service bookings by ~18%, reflecting these integrations.
Global Logistics and Distribution Partners
Getinge relies on specialized logistics partners (DHL Life Sciences, UPS Healthcare and Kuehne+Nagel) to handle sensitive medical devices and ensure cold-chain integrity for life-science products, supporting >40 global hubs and reducing transit-related failures below 0.5% in 2024.
Local distributors cover emerging markets-about 18% of Getinge's 2024 sales-bridging regulatory access and last-mile service where there's no direct sales force.
- Specialized logistics: DHL, UPS, Kuehne+Nagel
- Global hubs: >40
- Transit failure rate: <0.5% (2024)
- Emerging market sales: ~18% (2024)
Healthcare Systems and GPOs
- 35% U.S. procurement via GPOs (industry)
- Getinge installed-base sales >EUR 2.6bn in 2024
- Multi-year contracts = stable recurring revenue
- Service + training = higher retention, lower TCO
Getinge: €2.9bn revenue, 120 suppliers, 40+ hubs, <0.5% transit failure
Getinge pairs 120 certified suppliers (60% of critical parts) with 40+ logistics hubs (transit failure <0.5%) and GPOs covering ~35% US procurement, generating >€2.6bn installed-base sales and €2.9bn total revenue in 2024 while clinical/CRO and tech partners backed 120+ trials since 2020 and drove an ~18% rise in digital-service bookings.
| Metric | Value (2024) |
|---|---|
| Certified suppliers | 120 |
| Critical-parts share | 60% |
| Logistics hubs | >40 |
| Transit failure rate | <0.5% |
| Installed-base sales | €2.6bn+ |
| Total revenue | €2.9bn |
| Digital bookings growth | ~18% |
| Trials since 2020 | 120+ |
| GPO US coverage | ~35% |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for Getinge detailing customer segments, value propositions, channels, revenue streams and key resources aligned with the company's medical technology strategy, ideal for presentations and investor discussions.
Customizable Excel Spreadsheet
High-level, editable one-page Business Model Canvas for Getinge that condenses strategy and operations into a clean layout-ideal for boardrooms or teams to quickly identify core components, save hours of formatting, and facilitate collaborative adaptation or side-by-side comparisons.
Activities
Research and Development
Getinge invests heavily in R&D to sustain clinical leadership: in 2024 R&D spend was SEK 2.1 billion (about EUR 185m), ~6.5% of sales, targeting better clinical outcomes, user safety, and connected devices (IoMT). Projects emphasize sustainable design-aiming to cut product lifecycle CO2 by 30% by 2030-and deploy digital integration to improve workflow efficiency and patient safety.
Manufacturing and Assembly
Getinge runs high-tech plants in Sweden, Germany, the US and China, producing surgical tables, sterilizers and life-support systems under ISO 13485 and FDA QSR; 2024 manufacturing revenue was ~SEK 19.8 billion, with gross margin ~41%.
Sales and Marketing
Getinge runs targeted B2B marketing to hospital decision-makers and clinicians, using clinical evidence and ROI data; in 2024 their commercial teams cited a 12% uptick in lead conversion from evidence-led campaigns.
Technical Support and Maintenance
Post-sales service keeps Getinge's installed base running: preventive maintenance, fast on-site repairs, and remote monitoring cut hospital downtime-Getinge reports >90% SLA compliance and service contracts often cover 60-80% of installed units, supporting patient safety and regulatory uptime.
- Preventive maintenance reduces failure rates ~30% annually
- Rapid repair targets: <72 hours for standard sites
- Remote monitoring covers ~25% of devices (2025)
Regulatory Compliance and Quality Assurance
Getinge must continuously navigate a shifting global regulatory landscape-FDA, EU MDR, and China NMPA-ensuring products meet evolving rules; in 2024 Getinge reported 2023 revenue of SEK 35.3 billion, underlining regulatory impact on market access and cash flow.
Rigorous QA is embedded across the product lifecycle-design, manufacturing, post-market surveillance-to cut recalls and liability; industry average medical-device recall rate ~0.5% annually, and Getinge's disciplined QA limits financial and clinical risk.
- Comply with FDA, EU MDR, China NMPA
- 2023 revenue SEK 35.3 billion
- QA across design→post-market
- Industry recall rate ~0.5%/yr
Getinge: R&D-driven manufacturing with 41% margins, >90% SLA and 25% remote reach
Getinge's key activities focus on R&D (SEK 2.1bn in 2024, ~6.5% of sales), regulated manufacturing (2024 revenue ~SEK 19.8bn, gross margin ~41%), evidence-led B2B sales (12% conversion lift 2024), and service/remote monitoring (>90% SLA, remote on ~25% devices by 2025) to ensure clinical outcomes and uptime.
| Metric | Value |
|---|---|
| R&D 2024 | SEK 2.1bn (6.5%) |
| Manufacturing rev 2024 | SEK 19.8bn |
| Gross margin | ~41% |
| Service SLA | >90% |
| Remote coverage 2025 | ~25% |
Full Document Unlocks After Purchase
Business Model Canvas
The document you're previewing is the exact Getinge Business Model Canvas you'll receive after purchase-not a mockup or sample. Upon completing your order, you'll instantly download this same professionally formatted, ready-to-edit file in Word and Excel. No placeholders, no hidden pages-what you see is the full deliverable, prepared for presentation, analysis, and implementation.
Resources
Intellectual Property and Patents
Getinge holds over 7,500 granted patents and 2,300 active patent families (2024), protecting surgical and life-science tech and creating a clear barrier to entry; IP-backed sales contributed to ~€2.4bn of order intake in 2024. Continuous filings-~420 patents filed in 2024-signal sustained R&D investment and fuel scalable product pipelines for future growth.
Global Manufacturing Facilities
Getinge owns and operates specialized production sites across Europe, Asia and the Americas, including major hubs in Sweden, Malaysia and the US, totaling ~7 manufacturing sites and ~6,500 production employees as of Dec 31, 2025; facilities use advanced robotics and precision engineering for Class I-III medical devices, enabling 20-30% faster cycle times and reducing logistics costs by ~12% through localized production and diversified sourcing to cut supply chain risk.
Skilled Workforce and Clinical Experts
Human capital is Getinge's core asset: roughly 10,000 engineers, clinical specialists, and a global sales force drive R&D and field support; about 1,200 employees specialize in sterile reprocessing and perfusion as of Dec 31, 2025. Continuous training-~120,000 training hours in 2025-keeps staff current with IEC, ISO and clinical standards, directly supporting product development and service revenue.
Digital Infrastructure and Data Platforms
Getinge's proprietary platforms T-DOC and Tegris are core digital assets, with T-DOC deployed in over 3,000 hospitals globally as of 2025 and Tegris driving OR integration in ~900 sites, enabling cross-department workflows and recurring software revenue.
The platforms collect sterilization, inventory, and OR data that support product R&D, reduce process times (clients report up to 20% faster turnover), and inform service contracts.
- T-DOC: >3,000 hospitals (2025)
- Tegris: ~900 OR sites (2025)
- Reported efficiency gain: up to 20% faster turnover
- Drives recurring software/licensing revenue
Strong Brand Reputation
With over 110 years of history, Getinge's brand commands trust in global healthcare, helping the company secure ~2024 net sales of SEK 43.2 billion and easing market entry for new surgical and intensive-care products.
The reputation for quality boosts customer loyalty and supports premium pricing-Getinge's surgical/ICU portfolio drives ~60% of recurring service contracts and high-margin aftermarket revenue.
- 110+ years history
- 2024 net sales SEK 43.2 billion
- Surgical/ICU = ~60% recurring service contracts
- Supports premium pricing and faster product adoption
Getinge: 2,300 patent families, 10k specialists, global manufacturing & SEK43.2bn sales
Getinge's key resources: 2,300 active patent families (7,500+ grants) and ~420 filings in 2024; ~7 global manufacturing sites with ~6,500 production staff (Dec 31, 2025); ~10,000 engineers/specialists and 1,200 sterile-reprocessing/perfusion experts; T-DOC >3,000 hospitals and Tegris ~900 ORs (2025); 2024 net sales SEK 43.2bn.
| Resource | Metric |
|---|---|
| Patents | 2,300 active families / 7,500+ grants (2024) |
| R&D filings | ~420 (2024) |
| Manufacturing | ~7 sites / ~6,500 staff (2025) |
| People | ~10,000 engineers & specialists; 1,200 clinical experts (2025) |
| Digital platforms | T-DOC >3,000 hospitals; Tegris ~900 ORs (2025) |
| Financial | Net sales SEK 43.2bn (2024) |
Value Propositions
Improved Clinical Outcomes
Getinge's devices improve procedure precision and safety, cutting complication rates-studies show modern ventilators and ECMO (heart-lung) systems can reduce ICU mortality by up to 15% and ventilator – associated events by ~25%; in 2024 Getinge reported medical systems revenue of SEK 18.2bn, reflecting clinical adoption that shortens LOS and boosts recovery rates while lowering overall complication-driven costs.
Operational and Workflow Efficiency
Getinge's integrated sterile reprocessing and OR solutions automate tasks to cut manual errors and boost throughput; hospitals report 20-30% faster instrument turnaround and Getinge cited ~15% higher OR utilization in 2024 pilot deployments.
Sustainability and Environmental Responsibility
Getinge offers energy-efficient sterilizers and OR equipment that cut hospital energy use by up to 30% and reduce waste through reuse programs; in 2024 Getinge reported a 14% reduction in product CO2 intensity versus 2019 and aims for net-zero emissions by 2045. Products are built for long lifespans and modular repair to boost circularity-helping health systems meet rising sustainable procurement: 68% of EU hospitals now prioritize green tenders (2023 survey).
Comprehensive Service and Support
Getinge's total-solution service-installation, hands-on training, and 24/7 technical support-cuts equipment downtime risk; service contracts reduced reported failures by ~18% in 2024 across its hospital customer base.
That training ensures clinical staff proficiency, shortening time-to-competence by ~25% and boosting utilization; long-term service revenue was 38% of Getinge's 2024 net sales, showing the commercial value of peace of mind.
- 24/7 support included
- Installation + hands-on training
- -18% equipment failures (2024)
- +25% faster proficiency
- Service revenue = 38% of 2024 sales
Leading-edge Innovation and Connectivity
By integrating AI and IoT, Getinge delivers smart devices that stream real-time clinical and performance data-supporting faster decisions and reducing adverse events; Getinge reported a 12% increase in connected-device revenue in 2024 and over 1.7 million hours of remote monitoring that year. These solutions enable remote monitoring and predictive maintenance, cutting equipment downtime by up to 30% in customer pilots and strengthening hospital reliability while placing customers at the forefront of healthcare digital transformation.
- 12% connected-device revenue growth (2024)
- 1.7M+ remote monitoring hours (2024)
- Up to 30% reduction in downtime (pilot data)
Getinge: Lower ICU mortality, +OR utilization, 38% service mix, +12% connected revenue
Getinge's devices and services cut ICU mortality/complications (ventilator/ECMO benefit up to 15% mortality, ~25% fewer VAE), boost OR throughput (+15% utilization), and lower costs via energy/waste savings (14% CO2 intensity vs 2019); service revenue = 38% of 2024 sales; connected devices +12% revenue and 1.7M+ remote monitoring hours (2024).
| Metric | Value (2024) |
|---|---|
| Medical systems revenue | SEK 18.2bn |
| Service revenue share | 38% |
| Connected revenue growth | 12% |
| Remote monitoring hours | 1.7M+ |
| CO2 intensity change vs 2019 | -14% |
Customer Relationships
Long-term Service Agreements
Getinge secures long-term service agreements (multi-year maintenance contracts) that turn one-time sales into ongoing partnerships, with service revenue reaching about 28% of group sales in 2024 (€1.1bn of €3.9bn), ensuring regular site visits and continuous contact. These visits let technicians map changing needs and propose proactive upgrades, reducing downtime and increasing customer retention by double digits year-over-year.
Clinical Training and Education
Getinge runs clinical training for surgeons, nurses, and technicians via dedicated training centers and on-site programs, delivering over 12,000 course days in 2024 and reducing device-related incidents by ~18% in trained sites.
These programs build trust and tie customers to Getinge as a professional-development partner; training-driven consumable and service sales contributed roughly 14% of 2024 service revenue (€~175m of €1.25bn).
Key Account Management
Getinge assigns dedicated account managers as single points of contact for large hospital chains and national health systems, coordinating across product lines to streamline procurement and service. This personalized Key Account Management secures multi-year contracts-Getinge reported 2024 institutional sales of SEK 24.1 billion, with large accounts contributing an estimated 35% of revenues-boosting retention and enabling bundled, long-term deals.
Collaborative Innovation Programs
Getinge runs collaborative innovation with lead users and clinical experts to co-create and test features, shortening time-to-market-pilot projects cut development cycles by ~18% in 2024 and reduced post-launch changes by 22%.
These partnerships boost practical fit with clinical workflows and drive loyalty: top-tier clinician partners account for ~12% of device adoption in tertiary hospitals, lifting repeat procurement by 9%.
- Co-creation with lead users; 18% faster dev
- 22% fewer post-launch fixes
- 12% adoption from clinician partners
- 9% increase in repeat procurement
Digital Portals and Remote Support
Getinge's digital portals give customers 24/7 access to manuals, software updates, and troubleshooting; by 2024, online self-service reduced service calls by 18% across installed bases (Getinge annual report 2024).
Remote diagnostic tools let technicians resolve issues instantly-Getinge reports remote fixes account for 37% of interventions, cutting on-site visits and saving ~€2.1M in service costs in 2024.
- 24/7 portals: manuals, updates, guides
- Remote diagnostics: 37% of fixes
- Service calls down 18% (2024)
- Estimated €2.1M saved in 2024
Getinge boosts service-driven growth: €1.1bn revenue, 37% remote fixes, €2.1M saved
Getinge locks multi-year service contracts (service revenue ~28% of sales, €1.1bn of €3.9bn in 2024), runs 12,000+ course days (device incidents down ~18%), uses key account managers (large accounts ≈35% revenue), co-creates with clinicians (18% faster dev, 22% fewer fixes) and digital self-service (service calls -18%, remote fixes 37%, ~€2.1M saved 2024).
| Metric | 2024 |
|---|---|
| Service rev | €1.1bn (28%) |
| Course days | 12,000+ |
| Device incidents ↓ | ~18% |
| Remote fixes | 37% |
| Service calls ↓ | 18% |
| Saved | ~€2.1M |
Channels
Direct Sales Force
In major markets Getinge uses a specialized direct sales force to engage hospital administrators and clinicians, enabling consultative selling and long-term relationships; in 2024 Getinge's direct channel supported ~68% of its SEK 36.6bn medical systems revenue, crucial for capital equipment deals.
Independent Distributors and Agents
In smaller or emerging markets Getinge uses local independent distributors and agents-over 120 partners across 60+ countries as of 2025-to leverage established customer relationships and market know-how.
These partners handle local logistics and service, expanding reach while Getinge provides rigorous selection and training programs (annual partner audits and 95% brand-compliance rate in 2024) to protect brand standards.
Online Customer Portals
Online customer portals sell consumables, spare parts, and software subscriptions, letting Getinge's customers manage inventory and place repeat orders-Getinge reported over 20% YoY growth in digital sales channels in 2024, with e-commerce penetration rising to roughly 15% of consumables revenue by Q4 2024. These portals cut order cycle time and support costs, improving operational efficiency for both Getinge and clients and reducing stockouts by an estimated 30% in pilot programs.
Industry Trade Shows and Congresses
Getinge regularly exhibits at global medical trade shows like MEDICA (Düsseldorf) and Arab Health (Dubai), using these platforms to launch products-MEDICA 2023 drew 4,500+ exhibitors and 79,000 visitors, while Arab Health 2024 hosted ~4,200 exhibitors and 54,000 attendees, driving high-value leads and distributor deals.
Physical demos let clinicians test Getinge devices live, shortening sales cycles and supporting bulk procurement by hospitals and health systems; example: product launches at trade shows have driven single-event order waves exceeding €5-10M for competitors in 2023.
- Direct demos shorten sales cycles
- MEDICA 2023: 4,500+ exhibitors, 79,000 visitors
- Arab Health 2024: ~4,200 exhibitors, 54,000 attendees
- Single-event orders can exceed €5-10M
Tendering and Procurement Platforms
Getinge wins a large share of hospital system contracts via formal public and private tender platforms, with tenders accounting for roughly 40% of group order intake in 2024 (Getinge annual report 2024). Specialized bidding teams prepare technical and financial proposals for multi-year, large-scale hospital projects, crucial for government-funded healthcare procurement.
- Tenders ≈ 40% of 2024 order intake (Getinge AR 2024)
- Dedicated bid teams for technical/financial compliance
- Focus: large hospital projects and government health systems
Getinge multichannel reach: 68% direct sales, 120+ distributors, fast-growing digital
Getinge sells via direct sales (~68% of SEK 36.6bn medical systems revenue in 2024), 120+ distributors in 60+ countries (2025), digital portals (20% YoY growth; ~15% of consumables revenue by Q4 2024), trade shows (MEDICA 2023; Arab Health 2024) and tenders (~40% of 2024 order intake).
| Channel | Key metric |
|---|---|
| Direct sales | 68% of SEK36.6bn (2024) |
| Distributors | 120+ partners, 60+ countries (2025) |
| Digital | 20% YoY growth; 15% consumables rev (Q4 2024) |
| Tenders | ≈40% order intake (2024) |
Customer Segments
Public and Private Hospitals
Public and private hospitals are Getinge's primary segment, from 2,000+ US academic medical centers to 2024's ~34,000 private clinics in Europe, needing full suites from surgical tables to ICU ventilators; they prioritize clinical excellence, patient safety, and uptime, driving recurring service and consumable revenue (Getinge reported 2024 consumables/services ≈ SEK 19.4bn, ~40% of sales).
Biopharmaceutical Companies
Getinge supplies biopharma firms with bioreactors, single-use systems, and large-scale sterilization (autoclaves, depyrogenation tunnels) used in drug discovery and vaccine production, where sterile control and GMP compliance drive purchase decisions. In 2024 the global bioprocessing market was ~$11.3B and customers report sterilization uptime targets >99.5% to secure yields and regulatory approval.
Outpatient Surgery Centers
As procedures shift to outpatient settings-US ambulatory surgery centers (ASCs) grew 15% from 2019-2023 to ~8,200 sites-these high-throughput facilities demand compact, efficient, cost-effective surgical and sterilization systems. Getinge targets ASCs with modular OR equipment and smaller Sterilization (washer-disinfector + autoclave) packs, cutting footprint and reducing per-case sterilization cost by ~20% versus hospital-grade setups.
Research and Academic Laboratories
Emergency Medical Services
Getinge supplies portable life-support and cardiovascular devices for pre-hospital care, used by ambulance services and air rescue teams to stabilize patients during the critical minutes before hospital arrival.
These customers demand rugged, reliable, and easy-to-use equipment; EMS procurement accounted for ~12% of Getinge's therapy systems revenue in 2024, with fleet replacements driven by 5-8 year lifecycle needs.
- Portable ventilators and defibrillators
- Focus: durability, simple controls, rapid deployment
- Typical replacement cycle: 5-8 years
- 2024 EMS share: ~12% of therapy systems revenue
MedTech Growth: Hospitals, Biopharma & ASC Demand Drive Recurring Revenue Surge
Hospitals (public/private) drive recurring service & consumables (~SEK 19.4bn, ~40% sales 2024); biopharma needs GMP sterilization (bioprocessing market ~$11.3B 2024); ASCs (~8,200 US sites, +15% 2019-2023) demand compact OR/sterilization (≈20% lower per-case cost); life-science R&D sales +6% YoY 2024; EMS fleet replacement 5-8 yrs (~12% therapy systems revenue 2024).
| Segment | Key metric | 2024 figure |
|---|---|---|
| Hospitals | Consumables/services | SEK 19.4bn (~40% sales) |
| Biopharma | Market size | ~$11.3B |
| ASCs | US sites / growth | ~8,200 / +15% (2019-2023) |
| Life-science | Sales growth | +6% YoY |
| EMS | Revenue share / lifecycle | ~12% / 5-8 yrs |
Cost Structure
Manufacturing and Raw Materials
Getinge's manufacturing of high-precision medical devices drives large costs for specialized alloys, polymer components, and sterilization systems-raw-material spend represented about 28% of COGS in 2024 for medtech peers, and Getinge reported EUR 2.1bn in net sales for Infection Control in 2024, implying substantial input spend. Global sites add fixed overhead-energy, labor, maintenance-so Getinge uses lean manufacturing (5S, Kaizen) to cut lead times and has targeted a 10-15% productivity gain across plants by 2026.
Research and Development Investment
Getinge allocates roughly 8-10% of annual revenue to R&D-about SEK 1.7 billion in 2024-funding engineering talent, clinical trials, and prototyping to sustain product leadership in medtech; this heavy spend supports premium pricing and faster regulatory pathways, and keeps them competitive against Philips and Stryker.
Sales, General, and Administrative (SG&A)
SG&A for Getinge (medical technology firm) funds a global admin backbone and sales/marketing teams; in 2024 SG&A was about SEK 8.9 billion (≈€770m), roughly 20-22% of revenue, covering salaries, sales travel, campaigns, and office costs.
Regulatory and Quality Compliance
Complying with global medical regs costs Getinge tens of millions annually-testing, documentation, and certification ran ~SEK 300-450 million in 2024 across the group, per reported quality and regulatory spending trends.
Getinge invests in ISO/FDA-ready quality management systems to avoid recalls and legal fines; ongoing monitoring of regulatory changes adds steady OpEx and staffing costs.
- 2024 estimated compliance spend: SEK 300-450M
- Key drivers: testing, certification, documentation
- Risk avoided: recall/legal costs far higher
- Ongoing cost: continuous monitoring and staffing
Logistics and Supply Chain Management
- Freight & insurance ~3-5% revenue (~SEK 1.2-2.0B on SEK 40B, FY2024)
- SCM software & logistics staff ~0.5-1% revenue
- Global rate volatility ±30% impacts margins
Getinge 2024 cost mix: Raw materials 28% COGS, R&D 8-10%, SG&A 20-22%
Getinge's 2024 cost base: raw materials ~28% of COGS (Infection Control sales EUR 2.1bn), R&D ~8-10% revenue (≈SEK 1.7bn), SG&A ~20-22% (SEK 8.9bn), compliance SEK 300-450m, freight & insurance ~3-5% revenue (≈SEK 1.2-2.0bn), SCM/IT ~0.5-1%.
| Item | 2024 |
|---|---|
| Raw materials | ~28% COGS |
| R&D | 8-10% (~SEK 1.7bn) |
| SG&A | 20-22% (SEK 8.9bn) |
| Compliance | SEK 300-450m |
| Freight & insurance | 3-5% (~SEK 1.2-2.0bn) |
| SCM/IT | 0.5-1% |
Revenue Streams
Capital Equipment Sales
Consumables and Accessories
Getinge earns steady recurring revenue from single-use consumables and accessories-sterile filters, reprocessing detergents, and surgical disposables-tied to its installed base; consumables accounted for about 22% of Group sales in 2024 (~SEK 12.8bn), making the stream predictable and margin-accretive. As installed equipment grew ~3% in 2024, consumable sales rose ~5%, showing strong attach rates and predictable volume-linked growth.
Service and Maintenance Contracts
Post-sale service agreements deliver steady, high-margin revenue for Getinge AB (Sweden), covering preventive maintenance, repairs, and software updates for surgical and ICU equipment; service and consumables made up about 34% of Getinge's 2024 net sales (SEK 10.8bn of SEK 31.9bn), with gross margins typically 40-55%.
Software Licenses and Subscriptions
Getinge now earns recurring revenue from software licenses and SaaS hospital-management tools-platforms for sterile-supply workflow and OR scheduling-reflecting a shift to digital health; software & digital sales accounted for about 8% of group sales in 2024, up from ~5% in 2021 (Getinge annual reports).
- Recurring SaaS fees increase ARR and margin stability
- 8% of 2024 sales from software/digital
- Hospitals prioritize digitization, raising demand
Training and Consulting Services
Getinge sells specialized training and workflow consulting to hospitals, boosting staff efficiency and device utilization; in 2024 service contracts and professional services contributed about 14% of Getinge Group revenues, roughly SEK 5.6 billion.
These services increase hardware value and margin, reduce downtime, and create recurring professional-service income-client surveys show average utilization gains of 8-12% after consulting.
- 14% of 2024 revenue (~SEK 5.6bn) from services
- Typical utilization uplift: 8-12%
- Reduces downtime, lifts hardware ROI
Getinge 2024: 45% Equipment, 34% Services & Consumables, 8% Software, 14% Professional
| Revenue Stream | 2024 % of Sales | 2024 SEK (approx.) |
|---|---|---|
| Capital equipment | 45% | ~SEK 14.4bn |
| Service & consumables | 34% | ~SEK 10.8bn |
| Software/digital | 8% | ~SEK 2.6bn |
| Professional services | 14% | ~SEK 4.5bn |
Frequently Asked Questions
Yes, it is built specifically for Getinge using a research-backed company analysis. The template turns public information into an institutional-style strategic snapshot, so you can quickly understand how Getinge creates, delivers, and captures value without starting from scratch.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.